Equity Profile

CPRX

Catalyst Pharmaceuticals, Inc.

Health CareBiotechnology$3.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is performing compared to expectations.

$0.74

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$155M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs for patients with serious conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1 2026, Catalyst Pharmaceuticals reported an EPS of $0.79, significantly beating estimates by 36.21%. However, revenue figures were not disclosed, leaving some uncertainty about overall sales performance.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing patient needs in rare diseases.
Plans to enhance marketing efforts for existing therapies.

Expectations

Wall Street Expectations

Analysts expect Catalyst Pharmaceuticals to report strong earnings again, with a consensus EPS of $0.74 and revenue of $155 million. The company has a solid track record of beating earnings estimates, which may lead to positive market sentiment.

Bull Case

If the company exceeds EPS expectations and provides strong guidance for future revenue growth, it could see a significant boost in stock price, reflecting investor confidence.

Bear Case

Conversely, if the company fails to meet the EPS estimate or provides weak guidance, it could lead to a decline in stock price, as investors may question its growth prospects.

Key Metrics to Watch

EPS

$0.74

Earnings per share is a key indicator of profitability and will show how well the company is performing compared to expectations.

Revenue

$155M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.74?

A beat on EPS would reinforce the company's strong performance and could lead to a positive stock reaction.

What guidance will management provide for future revenue growth?

Investors will be keen to understand the company's outlook, as strong guidance could drive stock price higher.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the company's ability to leverage its existing therapies for revenue growth, especially given its recent strong performance.

Supporting Evidence

Catalyst has consistently beaten EPS estimates, indicating stronger operational execution than the market anticipates.

The options market is pricing a larger move than historical averages, suggesting that investors expect significant news or changes.

Management's commitment to expanding its product pipeline could drive future revenue beyond current estimates.

Key Risk

If the company provides strong guidance or exceeds revenue expectations, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching earnings as a reflection of the company's ability to maintain its growth trajectory amid competitive pressures.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 could signal potential issues with profitability and growth.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant potential move following the earnings report, indicating heightened investor interest and uncertainty.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests a potential stock increase of around +0.67% on the following day, confirming strong performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

Should the company miss EPS estimates, history indicates a potential decline of around -1.94%, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of new therapies in the pipeline.
2Details on sales performance for existing products.
3Management's commentary on market conditions and competitive landscape.
4Guidance on future revenue growth and strategic initiatives.
5Insights into patient feedback and market reception of current therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is performing compared to expectations.

$0.74

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$155M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to addressing patient needs in rare diseases.
Plans to enhance marketing efforts for existing therapies.

Expectations

Wall Street Expectations

Bull Case

If the company exceeds EPS expectations and provides strong guidance for future revenue growth, it could see a significant boost in stock price, reflecting investor confidence.

Bear Case

Conversely, if the company fails to meet the EPS estimate or provides weak guidance, it could lead to a decline in stock price, as investors may question its growth prospects.

Key Metrics to Watch

EPS

$0.74

Earnings per share is a key indicator of profitability and will show how well the company is performing compared to expectations.

Revenue

$155M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.74?

A beat on EPS would reinforce the company's strong performance and could lead to a positive stock reaction.

What guidance will management provide for future revenue growth?

Investors will be keen to understand the company's outlook, as strong guidance could drive stock price higher.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the company's ability to leverage its existing therapies for revenue growth, especially given its recent strong performance.

Supporting Evidence

Catalyst has consistently beaten EPS estimates, indicating stronger operational execution than the market anticipates.

The options market is pricing a larger move than historical averages, suggesting that investors expect significant news or changes.

Management's commitment to expanding its product pipeline could drive future revenue beyond current estimates.

Key Risk

If the company provides strong guidance or exceeds revenue expectations, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching earnings as a reflection of the company's ability to maintain its growth trajectory amid competitive pressures.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 could signal potential issues with profitability and growth.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant potential move following the earnings report, indicating heightened investor interest and uncertainty.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests a potential stock increase of around +0.67% on the following day, confirming strong performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

Should the company miss EPS estimates, history indicates a potential decline of around -1.94%, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of new therapies in the pipeline.
2Details on sales performance for existing products.
3Management's commentary on market conditions and competitive landscape.
4Guidance on future revenue growth and strategic initiatives.
5Insights into patient feedback and market reception of current therapies.